Acrivon Therapeutics Common Stock Statistics Share Statistics Acrivon Therapeutics Common Stock has 31.36M
shares outstanding. The number of shares has increased by 1.24%
in one year.
Shares Outstanding 31.36M Shares Change (YoY) 1.24% Shares Change (QoQ) 0.01% Owned by Institutions (%) 58.71% Shares Floating 22.16M Failed to Deliver (FTD) Shares 19,417 FTD / Avg. Volume 4.16%
Short Selling Information The latest short interest is 598.6K, so 1.91% of the outstanding
shares have been sold short.
Short Interest 598.6K Short % of Shares Out 1.91% Short % of Float 5.1% Short Ratio (days to cover) 2.14
Valuation Ratios The PE ratio is -25.25 and the forward
PE ratio is -0.53.
Acrivon Therapeutics Common Stock's PEG ratio is
0.28.
PE Ratio -25.25 Forward PE -0.53 PS Ratio 0 Forward PS 23.1 PB Ratio 11.51 P/FCF Ratio -29.72 PEG Ratio 0.28
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Acrivon Therapeutics Common Stock.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.55,
with a Debt / Equity ratio of 0.02.
Current Ratio 10.55 Quick Ratio 10.55 Debt / Equity 0.02 Debt / EBITDA -0.05 Debt / FCF -0.05 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.07M Employee Count 75 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -83.93% in the
last 52 weeks. The beta is 1.67, so Acrivon Therapeutics Common Stock's
price volatility has been higher than the market average.
Beta 1.67 52-Week Price Change -83.93% 50-Day Moving Average 1.28 200-Day Moving Average 4.04 Relative Strength Index (RSI) 41.97 Average Volume (20 Days) 466,375
Income Statement
Revenue n/a Gross Profit n/a Operating Income -89.2M Net Income -80.56M EBITDA -79.55M EBIT -80.56M Earnings Per Share (EPS) -0.24
Full Income Statement Balance Sheet The company has 39.82M in cash and 3.65M in
debt, giving a net cash position of 36.17M.
Cash & Cash Equivalents 39.82M Total Debt 3.65M Net Cash 36.17M Retained Earnings -196.98M Total Assets 176.35M Working Capital 137.78M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -65.67M
and capital expenditures -2.77M, giving a free cash flow of -68.44M.
Operating Cash Flow -65.67M Capital Expenditures -2.77M Free Cash Flow -68.44M FCF Per Share -0.2
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
